학술논문
Low-Density Lipoprotein Cholesterol Levels on Statins and Cardiovascular Event Risk in Stable Coronary Artery Disease ― An Observation From the REAL-CAD Study ―
Document Type
Journal Article
Author
Hiroki Shiomi; Hiroshi Iwata; Hirotoshi Watanabe; Hiroyuki Daida; Ichiro Sakuma; Katsumi Miyauchi; Kyohei Yamaji; Masahiro Natsuaki; Masunori Matsuzaki; Naritatsu Saito; Retsu Fujita; Ryozo Nagai; Satoru Suwa; Satoshi Iimuro; Takeshi Kimura; Takeshi Morimoto; Teruo Inoue; Toshiaki Toyota; Yasuo Ohashi; Yoshihisa Nakagawa; Yosuke Nishihata; Yukio Ozaki; Yutaka Furukawa
Source
Circulation Journal. 2023, 87(2):360
Subject
Language
English
ISSN
1346-9843
1347-4820
1347-4820
Abstract
Methods and Results: From the REAL-CAD study comparing high-dose (4 mg/day) with low-dose (1 mg/day) pitavastatin therapy in patients with stable coronary artery disease, 11,105 patients with acceptable statin adherence were divided into 3 groups according to the on-treatment LDL-C level at 6 months (<70 mg/dL, 70–100 mg/dL, and ≥100 mg/dL). The primary outcome measure was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, or unstable angina requiring emergent admission. The adjusted risks of the LDL-C <70 mg/dL group relative to the LDL-C 70–100 mg/dL group (reference) was not significantly different for the primary outcome measure in both 1 mg/day and 4 mg/day strata (HR 0.84, 95% CI 0.58–1.18, P=0.32, and HR 1.25, 95% CI 0.88–1.79, P=0.22). The adjusted risk of the LDL-C ≥100 mg/dL group relative to the reference group was not significant for the primary outcome measure in the 1 mg/day stratum (HR 0.82, 95% CI 0.60–1.11, P=0.21), whereas it was highly significant in the 4 mg/day stratum (HR 3.32, 95% CI 2.08–5.17, P<0.001).